|
Eine Ebene nach oben |
Gruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 39
2022
Buske, C.; Dreyling, M.; Alvarez-Larran, A.; Apperley, J.; Arcaini, L.; Besson, C.; Bullinger, L.; Corradini, P.; Della Porta, M. Giovanni; Dimopoulos, M.; D'Sa, S.; Eich, H. T.; Foa, R.; Ghia, P.; da Silva, M. G.; Gribben, J.; Hajek, R.; Harrison, C.; Heuser, M.; Kiesewetter, B.; Kiladjian, J. J.; Kroeger, N.; Moreau, P.; Passweg, J. R.; Peyvandi, F.; Rea, D.; Ribera, J.-M.; Robak, T.; San-Miguel, J. F.; Santini, V.; Sanz, G.; Sonneveld, P.; Lilienfeld-Toal, M. von; Wendtner, C.; Pentheroudakis, G. und Passamonti, F.
(2022):
Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus.
In: ESMO Open, Bd. 7, Nr. 2, 100403
2021
Hadi, I; Schummer, A.; Dreyling, M.; Eze, C.; Bodensohn, R.; Roengvoraphoj, O.; Belka, C. und Li, M.
(2021):
Effectiveness and tolerability of radiotherapy for patients with indolent non-Hodgkin's lymphoma: a monocenter analysis.
In: Scientific Reports, Bd. 11, Nr. 1, 22586
Dreyling, M.; Ghielmini, M.; Rule, S.; Salles, G.; Ladetto, M.; Tonino, S. H.; Herfarth, K.; Seymour, J. F. und Jerkeman, M.
(2021):
Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines tor diagnosis, treatment and follow-up.
In: Annals of Oncology, Bd. 32, Nr. 3: S. 298-308
Bishop, M. R.; Dickinson, M.; Purtill, D.; Barba, P.; Santoro, A.; Hamad, N.; Kato, K.; Sureda, A.; Greil, R.; Thieblemont, C.; Morschhauser, F.; Janz, M.; Flinn, I.; Rabitsch, W.; Kwong, Y.-L.; Kersten, M. J.; Minnema, M. C.; Holte, H.; Chan, E. H. L.; Martinez-Lopez, J.; Mueller, A. M. S.; Maziarz, R. T.; McGuirk, J. P.; Bachy, E.; Le Gouill, S.; Dreyling, M.; Harigae, H.; Bond, D.; Andreadis, C.; McSweeney, P.; Kharfan-Dabaja, M.; Newsome, S.; Degtyarev, E.; Awasthi, R.; del Corral, C.; Andreola, G.; Masood, A.; Schuster, S. J.; Jaeger, U.; Borchmann, P. und Westin, J. R.
(2021):
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.
In: New England Journal of Medicine, Bd. 386, Nr. 7: S. 629-639
Hadi, I.; Schummer, A.; Dreyling, M.; Eze, C.; Bodensohn, R.; Roengvoraphoj, O.; Belka, Claus 
ORCID: https://orcid.org/0000-0002-1287-7825 und Li, M.
(2021):
Effectiveness and tolerability of radiotherapy for patients with indolent non-Hodgkin's lymphoma: a monocenter analysis.
In: Scientific reports, Bd. 11, 22586
[PDF, 1MB]
ORCID: https://orcid.org/0000-0002-1287-7825 und Li, M.
(2021):
Effectiveness and tolerability of radiotherapy for patients with indolent non-Hodgkin's lymphoma: a monocenter analysis.
In: Scientific reports, Bd. 11, 22586
[PDF, 1MB]
2020
Al-Sawaf, O.; Robrecht, S.; Bahlo, J.; Fink, A. M.; Cramer, P.; Tresckow, J. von; Lange, E.; Kiehl, M.; Dreyling, M.; Ritgen, M.; Duerig, J.; Tausch, E.; Schneider, C.; Stilgenbauer, S.; Wendtner, C. M.; Fischer, K.; Goede, V.; Hallek, M. und Eichhorst, B.
(2020):
Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials.
In: Leukemia, Bd. 35, Nr. 1: S. 169-176
2018
Rule, S.; Jurczak, W.; Jerkeman, M.; Rusconi, C.; Trneny, M.; Offner, F.; Caballero, D.; Joao, C.; Witzens-Harig, M.; Hess, G.; Bence-Bruckler, I.; Cho, S-G; Thieblemont, C.; Zhou, W.; Henninger, T.; Goldberg, J.; Vermeulen, J. und Dreyling, M.
(2018):
Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study.
In: Leukemia, Bd. 32, Nr. 8: S. 1799-1803
2017
Provencio Pulla, M.; Santoro, A.; Mollica, L.; Leppa, S.; Follows, G.; Lenz, G.; Kim, W. S.; Nagler, A.; Panayiotidis, P.; Demeter, J.; Ozcan, M.; Kosinova, M.; Bouabdallah, K.; Morschhauser, F.; Ishida, T.; Huang, L.; Garcia-Vargas, J.; Childs, B. H.; Zinzani, P. L. und Dreyling, M.
(2017):
Copanlisib treatment in patients with relapsed or refractory indolent B-cell lymphoma: Subgroup analyses from the CHRONOS-1 study.
In: Annals of Oncology, Bd. 28
Liu, L.; Köchert, K.; Seidel, H.; Garcia-Vargas, J.; Childs, B. H.; Follows, G.; Bouabdallah, K.; Dreyling, M. und Pena, C.
(2017):
Tumor gene expression signatures of BCR/PI3K dependence in association with copanlisib monotherapy activity in heavily pretreated patients with indolent NHL and follicular lymphoma.
In: Annals of Oncology, Bd. 28
Dreyling, M.; Hess, G. und Krekeler, G.
(2017):
Evaluation of safety, tolerability and efficacy of Temsirolimus in patients (pts) with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice.
In: Oncology Research and Treatment, Bd. 40: S. 72
Herold, M.; Hoster, E.; Unterhalt, M.; Hänel, M.; Prange-Krex, G.; Forstpointner, R.; Florschütz, A.; Gräven, U.; Frickhofen, N.; Wulf, G.; Lengfelder, E.; Lerchenmüller, C.; Schlag, R.; Dierlamm, J.; Fischer von Weikersthal, L.; Ahmed, A.; Harich, H.-D.; Rosenwald, A.; Klapper, W.; Dreyling, M. und Hiddemann, W.
(2017):
Rituximab maintenance versus observation after immunochemotherapy (R-CHOP, R-MCP, R-FCM) in previously untreated follicular lymphoma: a randomized trial of GLSG and OSHO.
In: Oncology Research and Treatment, Bd. 40: S. 74
Zinzani, P. L.; Santoro, A.; Leppa, S.; Demeter, J.; Follows, G. A.; Lenz, G.; Kim, W. S.; Mollica, L.; Nagler, A.; Diong, C. P.; Provenciio, M.; Stevens, D. A.; Trevarthen, D.; Maagnoli, M.; Cupit, L.; Yin, S.; Hiemeyer, F.; Garcia-Vargas, J.; Childs, B. H. und Dreyling, M.
(2017):
Efficacy and safety of Copanlisib in patients with relapsed/refractory follicular lymphoma: a subset analysis of the Chronos-1 study.
In: Haematologica, Bd. 102: S. 314-315
Fischer, L.; Mayer, A.; Irger, M.; Freysoldt, B.; Zimmermann, Y.; Hutter, G.; Hiddemann, W. und Dreyling, M.
(2017):
CDK4/6-INHIBITION BY ABEMACICLIB INDUCES POTENT EARLY G1-ARREST IN MCL CELL LINES AND SHOWS SEQUENCE-SPECIFIC INTERACTIONS WITH CYTARABINE AND IBRUTINIB.
In: Haematologica, Bd. 102: S. 575
Jerkeman, M.; Hallek, M.; Dreyling, M.; Thieblemont, C.; Kimby, E. und Staudt, L.
(2017):
Targeting of B-cell receptor signalling in B-cell malignancies.
In: Journal of internal Medicine, Bd. 282, Nr. 5: S. 415-428
Pott, C.; Delfau, M.; Macintyre, E.; Ribrag, V.; Klapper, W.; Unterhalt, M.; Kneba, M.; Hiddemann, W.; Hermine, O.; Kluin-Nelemans, H.; Dreyling, M. und Hoster, E.
(2017):
Implications of deep molecular response after induction and in maintenance treatment in elderly patients with mantle cell lymphoma: updated results of the randomized EU-MCL elderly trial.
In: Oncology Research and Treatment, Bd. 40: S. 13
Dreyling, M.; Campo, E.; Hermine, O.; Jerkeman, M.; Gouill, S. le; Rule, S.; Shpilberg, O.; Walewski, J. und Ladetto, M.
(2017):
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
In: Annals of Oncology, Bd. 28: S. 62-71
Dreyling, M.; Santoro, A.; Mollica, L.; Leppa, S.; Follows, G. A.; Lenz, G.; Kim, W. S.; Nagler, A.; Panayiotidis, P.; Demeter, J.; Ozcan, M.; Kosinova, M.; Bouabdallah, K.; Morschhauser, F.; Stevens, D. A.; Trevarthen, D.; Giurescu, M.; Kupit, L.; Childs, B. H. und Zinzani, P. L.
(2017):
Copanlisib (COP) in patients with relapsed or refractory indolent B-cell lymphoma: primary results of the pivotal Chronos-1 study.
In: Oncology Research and Treatment, Bd. 40: S. 12
Maddocks, K.; Gonzalez Barca, E.; Jurczak, W.; Liberati, A. M.; Duell, J.; Nagy, Z.; Papaj-K, T.; Andre, M.; Kalakonda, N.; Dreyling, M.; Zinzani, P. L.; Ambarkhane, S.; Weirather, J. und Salles, G.
(2017):
L-Mind: MOR208 Combined with Lenalidomide (Len) In Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R Dlbcl)-A Single-Arm Phase II Study.
In: Haematologica, Bd. 102: S. 174
Duell, J.; Gonzalez Barca, E.; Liberati, A. M.; Salles, G.; Gaidano, G.; Jurczak, W.; Nagy, Z.; Papajlk, T.; Andre, M.; Zinzani, P. L.; Kalakonda, N.; Ambarkhane, S.; Weirather, J.; Maddocks, K. und Dreyling, M.
(2017):
L-MIND: MOR208 combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large B-cell lymphoma (R-R DLBCL) - a single-arm phase II study.
In: Oncology Research and Treatment, Bd. 40: S. 68
Younes, A.; Hilden, P.; Coiffier, B.; Hagenbeek, A.; Salles, G.; Wilson, W.; Seymour, J. F.; Kelly, K.; Gribben, J.; Pfreunschuh, M.; Morschhauser, F.; Schoder, H.; Zelenetz, A. D.; Rademaker, J.; Advani, R.; Valente, N.; Fortpied, C.; Witzig, T. E.; Sehn, L. H.; Engert, A.; Fisher, R. I.; Zinzani, P.-L.; Federico, M.; Hutchings, M.; Bollard, C.; Trneny, M.; Elsayed, Y. A.; Tobinai, K.; Abramson, J. S.; Fowler, N.; Goy, A.; Smith, M.; Ansell, S.; Kuruvilla, J.; Dreyling, M.; Thieblemont, C.; Little, R. F.; Aurer, I.; Oers, M. H. J. van; Takeshita, K.; Gopal, A.; Rule, S.; Vos, S. de; Kloos, I.; Kaminski, M. S.; Meignan, M.; Schwartz, L. H.; Leonard, J. P.; Schuster, S. J. und Seshan, V. E.
(2017):
International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).
In: Annals of Oncology, Bd. 28, Nr. 7: S. 1436-1447
Dreyling, M.; Hess, G. und Krekeler, G.
(2017):
Evaluation of safety, tolerability and efficacy of temsirolimus in patients (pts) with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice.
In: Annals of Oncology, Bd. 28
Dreyling, M.; Aukema, S. M.; Rosenwald, A.; Canoni, D.; Rymkiewicz, G.; Thorns, C.; Hartmann, S.; Kluin-Nelemans, H.; Hermine, O.; Klapper, W. und Hoster, E.
(2017):
P53 but not SOX11 IHC has prognostic value independent of MIPI and Ki-67 in prospective trials of the European-MCL Network.
In: Oncology Research and Treatment, Bd. 40: S. 69
Seiler, T. und Dreyling, M.
(2017):
Bruton's tyrosine kinase inhibitors in B-cell lymphoma: current experience and future perspectives.
In: Expert Opinion On investigational Drugs, Bd. 26, Nr. 8: S. 909-915
Dreyling, M.; Morschhauser, F.; Bouabdallah, K.; Bron, D.; Cunningham, D.; Assouline, S. E.; Verhoef, G.; Linton, K.; Thieblemont, C.; Vitolo, U.; Hiemeyer, F.; Giurescu, M.; Garcia-Vargas, J.; Gorbatchevsky, I.; Liu, L.; Koechert, K.; Pena, C.; Neves, M.; Childs, B. H. und Zinzani, P. L.
(2017):
Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma.
In: Annals of Oncology, Bd. 28, Nr. 9: S. 2169-2178
2016
Tam, C.; Roberts, A.; Anderson, M. A.; Dawson, S. J.; Hicks, R.; Pott, C.; Westerman, D.; Burke, G.; Kamel, S.; Dreyling, M.; Dawson, M. und Seymour, J.
(2016):
The combination of ibrutinib and venetoclax (ABT-199) rapidly achieves complete remissions in patients with relapsed/refractory mantle cell lymphoma: Preliminary results of the phase II AIM study.
In: Haematologica, Bd. 101: S. 103
Ferrero, S.; Pastore, A.; Scholz, C. W.; Forstpointner, R.; Pezzutto, A.; Bergmann, L.; Trümper, L.; Finke, J.; Keller, U.; Ghione, P.; Passera, R.; Hiddemann, W.; Weigert, O.; Unterhalt, M. und Dreyling, M.
(2016):
Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL Network Phase II Trial.
In: Leukemia, Bd. 30, Nr. 4: S. 984-987
Dreyling, M.; Morschhauser, F.; Bouabdallah, K.; Cunningham, D.; Bron, D.; Linton, K.; Assouline, S.; Verhoef, G.; Thieblemont, C.; Vitolo, U.; Garcia-Vargas, J.; Gorbatchevsky, I.; Neves, M.; Grunert, J.; Hiemeyer, F.; Childs, B. H. und Zinzani, P. L.
(2016):
Phase 2a study of the Phosphatidylinositol-3-Kinase (PI3K) inhibitor Copanlisib in patients with relapsed/refractory, indolent or aggressive lymphoma.
In: Haematologica, Bd. 101: S. 104
Lenz, G.; Balasubramanian, S.; Goldberg, J.; Rizo, A.; Schaffer, M.; Phelps, C.; Rule, S. und Dreyling, M.
(2016):
Sequence variants in patients with primary and acquired resistance to Ibrutinib in the phase 3 MCL3001 (RAY) trial.
In: Haematologica, Bd. 101: S. 155
Rule, S.; Dreyling, M.; Hess, G.; Auer, R.; Kahl, B.; Cavazos, N.; Liu, B.; Clow, F.; Goldberg, J.; Beaupre, D.; Vermeulen, J.; Wildgust, M. und Wang, M.
(2016):
Overall survival outcomes in patients with mantle-cell lymphoma (MCL) treated with Ibrutinib in a pooled analysis of 370 patients from 3 international open-label studies.
In: Haematologica, Bd. 101: S. 155
Hutter, G.; Zimmermann, Y.; Zoellner, A.; Irrgang, P.; Arnd, J.; Hiddemann, W. und Dreyling, M.
(2016):
Mode of action of different PI3K-inhibitors in mantle cell lymphoma.
In: Haematologica, Bd. 101: S. 271
Witzens-Harig, M.; Keller, U.; Viardot, A.; Buske, C.; Hönig, E.; Crombe, A.; Brandt, J.; Meissner, J.; Ho, A.; La Rosee, P.; Marks, R.; Dreyling, M. und Hess, G.
(2016):
Safety and clinical activity of temsirolimus in combination with Rituximab and DHAP in patients with relapsed or refractory diffuse large B-cell lymphoma - preliminary results of the storm trial.
In: Haematologica, Bd. 101: S. 390
Dreyling, M.; Krekeler, G.; Neuhof, A.; Woike, M.; Hess, G. und Kalanovic, D.
(2016):
Evaluation of safety, tolerability and efficacy of temsirolimus in patients (pts) with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice.
In: Annals of Oncology, Bd. 27
Dreyling, M.; Ghielmini, M.; Rule, S.; Salles, G.; Vitolo, U. und Ladetto, M.
(2016):
Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
In: Annals of Oncology, Bd. 27:
v83-v90
Ladetto, M.; Buske, C.; Hutchings, M.; Dreyling, M.; Gaidano, G.; Le Gouill, S.; Luminari, S.; Pott, C.; Zamò, A. und Zucca, E.
(2016):
ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia.
In: Annals of Oncology, Bd. 27, Nr. 12: S. 2149-2160
Liu, L.; Koechert, K.; Cheng, J.; Garcia-Vargas, J.; Childs, B. H.; Dreyling, M. und Pena, C.
(2016):
Tumor gene expression profiles associated with single-agent copanlisib activity in heavily pretreated patients with indolent and aggressive non-hodgkin lymphoma (NHL).
In: Haematologica, Bd. 101: S. 571
Kvint, R.; Zimmermann, Y.; Hutter, G.; Hiddemann, W. und Dreyling, M.
(2016):
High efficiency of the pan-PI3K/mTOR inhibitor, PQR-309, in MCL.
In: Oncology Research and Treatment, Bd. 39: S. 153-154
Hutter, G.; Zimmermann, Y.; Bamopoulos, S. A.; Irger, M.; Hiddemann, W. und Dreyling, M.
(2016):
Synergistic effect of inhibition of multiple PI3K-isoforms due to the differential mode of action of single PI3K-isoform inhibitors in mantle cell lymphoma.
In: Oncology Research and Treatment, Bd. 39: S. 154
Dreyling, M.; Krekeler, G.; Neuhof, A.; Woike, M.; Hess, G. und Kalanovic, D.
(2016):
Evaluation of safety, tolerability and efficacy of Temsirolimus in patients (pts) with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice.
In: Oncology Research and Treatment, Bd. 39: S. 156
Al-Sawaf, O.; Kluth, S.; Bahlo, J.; Hopfinger, G.; Fink, A. M.; Cramer, P.; Maurer, C.; Bergmann, M.; Dreyling, M.; Lange, E.; Kneba, M.; Stilgenbauer, S.; Kiehl, M. G.; Jäger, U.; Wendtner, C. M.; Fischer, K.; Hallek, M. und Eichhorst, B.
(2016):
Impact of gender on outcome after chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab (FCR) or bendamustin plus R (BR) in CLL patients: a pooled analysis of the German CLL Study Group (GCLLSG).
In: Oncology Research and Treatment, Bd. 39: S. 212-213